|
2022 Journal Article Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteriaLarkin, James, Weber, Jeffrey, Del Vecchio, Michele, Gogas, Helen, Arance, Ana M., Dalle, Stephane, Cowey, C. Lance, Schenker, Michael, Grob, Jean-Jacques, Chiarion-Sileni, Vanna, Márquez-Rodas, Iván, Butler, Marcus O., Di Giacomo, Anna Marie, Middleton, Mark R., De la Cruz-Merino, Luis, Arenberger, Petr, Atkinson, Victoria, Hill, Andrew, Fecher, Leslie A., Millward, Michael, Khushalani, Nikhil I., Queirolo, Paola, Long, Georgina V., Lobo, Maurice, Askelson, Margarita, Ascierto, Paolo A. and Mandalá, Mario (2022). Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria. European Journal of Cancer, 173, 285-296. doi: 10.1016/j.ejca.2022.06.041 |
|
2022 Conference Publication Radiomics biomarkers are associated with survival in patients with oesophageal adenocarcinomaAoude, L.G., Bonazzi, V.F., Brosda, S., Wong, B., Moradi, H., Lonie, J., Bradford, J., Bloxham, C., Atkinson, V.G., Law, P., Lampe, G., Smithers, M., Waddell, N., Vegh, V., Miles, K. and Barbour, A.P. (2022). Radiomics biomarkers are associated with survival in patients with oesophageal adenocarcinoma. ESMO Congress 2022, Singapore, 9 - 13 September 2022. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.annonc.2022.07.1357 |
|
2022 Journal Article Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort studyDimitriou, F., Namikawa, K., Reijers, I. L.M., Buchbinder, E. I., Soon, J. A., Zaremba, A., Teterycz, P., Mooradian, M. J., Armstrong, E., Nakamura, Y., Vitale, M. G., Tran, L. E., Bai, X., Allayous, C., Provent-Roy, S., Indini, A., Bhave, P., Farid, M., Kähler, K. C., Mehmi, I., Atkinson, V., Klein, O., Stonesifer, C. J., Zaman, F., Haydon, A., Carvajal, R. D., Hamid, O., Dummer, R., Hauschild, A. ... Long, G. V. (2022). Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study. Annals of Oncology, 33 (9), 968-980. doi: 10.1016/j.annonc.2022.06.004 |
|
2022 Journal Article In-depth characterisation of real-world advanced melanoma patients receiving immunotherapies and/or targeted therapies: a case seriesSanjida, Saira, Betz-Stablein, Brigid, Atkinson, Victoria, Janda, Monika, Barsoum, Ramez, Edwards, Harrison Aljian, Chiu, Frank, Tran, My Co, Soyer, H. Peter and Schaider, Helmut (2022). In-depth characterisation of real-world advanced melanoma patients receiving immunotherapies and/or targeted therapies: a case series. Cancers, 14 (11) 2801, 2801. doi: 10.3390/cancers14112801 |
|
2022 Conference Publication Outcomes of neoadjuvant and definitive CROSS (carboplatin and paclitaxel chemoradiotherapy) in oesophageal cancerIqbal, Samreen, Atkinson, Victoria, Arneil, Melissa, Andelkovic, Vladimir and Roberts, Kate Elizabeth (2022). Outcomes of neoadjuvant and definitive CROSS (carboplatin and paclitaxel chemoradiotherapy) in oesophageal cancer. 2022 ASCO Annual Meeting, Chicago, IL United States, 3-7 June 2022. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2022.40.16_suppl.e16033 |
|
2022 Journal Article Treatment Approaches for Melanomas That Relapse After Adjuvant or Neoadjuvant TherapyNg, Gary, Xu, Wen and Atkinson, Victoria (2022). Treatment Approaches for Melanomas That Relapse After Adjuvant or Neoadjuvant Therapy. Current Oncology Reports, 24 (10), 1273-1280. doi: 10.1007/s11912-022-01288-y |
|
2022 Journal Article Stereotactic radiosurgery for melanoma brain metastases: Concurrent immune checkpoint inhibitor therapy associated with superior clinicoradiological response outcomesShanker, Mihir D., Garimall, Sidyarth, Gatt, Nick, Foley, Heath, Crowley, Samuel, Le Cornu, Emma, Muscat, Kendall, Soon, Wei, Atkinson, Victoria, Xu, Wen, Watkins, Trevor, Huo, Michael, Foote, Matthew C. and Pinkham, Mark B. (2022). Stereotactic radiosurgery for melanoma brain metastases: Concurrent immune checkpoint inhibitor therapy associated with superior clinicoradiological response outcomes. Journal of Medical Imaging and Radiation Oncology, 66 (4), 536-545. doi: 10.1111/1754-9485.13403 |
|
2022 Journal Article Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlusAtkinson, Victoria, Robert, Caroline, Grob, Jean J., Gogas, Helen, Dutriaux, Caroline, Demidov, Lev, Gupta, Avinash, Menzies, Alexander M., Ryll, Bettina, Miranda, Flora, Banerjee, Hiya, Lau, Mike and Del Vecchio, Michele (2022). Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus. European Journal of Cancer, 163, 79-87. doi: 10.1016/j.ejca.2021.12.015 |
|
2022 Journal Article Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysisGoldinger, Simone M., Buder-Bakhaya, Kristina, Lo, Serigne N., Forschner, Andrea, McKean, Meredith, Zimmer, Lisa, Khoo, Chloe, Dummer, Reinhard, Eroglu, Zeynep, Buchbinder, Elizabeth I., Ascierto, Paolo A., Gutzmer, Ralf, Rozeman, Elisa A., Hoeller, Christoph, Johnson, Douglas B., Gesierich, Anja, Kölblinger, Peter, Bennannoune, Naima, Cohen, Justine V., Kähler, Katharina C., Wilson, Melissa A., Cebon, Jonathan, Atkinson, Victoria, Smith, Jessica L., Michielin, Olivier, Long, Georgina V., Hassel, Jessica C., Weide, Benjamin, Haydu, Lauren E. ... Menzies, Alexander M. (2022). Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. European Journal of Cancer, 162, 22-33. doi: 10.1016/j.ejca.2021.11.022 |
|
2022 Journal Article BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian settingScolyer, Richard A., Atkinson, Victoria, Gyorki, David E., Lambie, Duncan, O'Toole, Sandra, Saw, Robyn P.M., Amanuel, Benhur, Angel, Christopher M., Button-Sloan, Alison E., Carlino, Matteo S., Ch'ng, Sydney, Colebatch, Andrew J., Daneshvar, Dariush, Pires da Silva, Inês, Dawson, Tamara, Ferguson, Peter M., Foster-Smith, Erwin, Fox, Stephen B., Gill, Anthony J., Gupta, Ruta, Henderson, Michael A., Hong, Angela M., Howle, Julie R., Jackett, Louise A., James, Craig, Lee, C. Soon, Lochhead, Alistair, Loh, Daphne, McArthur, Grant A. ... Long, Georgina V. (2022). BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting. Pathology, 54 (1), 6-19. doi: 10.1016/j.pathol.2021.11.002 |
|
2021 Journal Article Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanomaEggermont, Alexander MM., Meshcheryakov, Andrey, Atkinson, Victoria, Blank, Christian U., Mandala, Mario, Long, Georgina V., Barrow, Catherine, Di Giacomo, Anna Maria, Fisher, Rosalie, Sandhu, Shahneen, Kudchadkar, Ragini, Ortiz Romero, Pablo Luis, Svane, Inge Marie, Larkin, James, Puig, Susana, Hersey, Peter, Quaglino, Pietro, Queirolo, Paola, Stroyakovskiy, Daniil, Bastholt, Lars, Mohr, Peter, Hernberg, Micaela, Chiarion-Sileni, Vanna, Strother, Matthew, Hauschild, Axel, Yamazaki, Naoya, van Akkooi, Alexander CJ., Lorigan, Paul, Krepler, Clemens ... Robert, Caroline (2021). Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. European Journal of Cancer, 158, 156-168. doi: 10.1016/j.ejca.2021.09.023 |
|
2021 Journal Article Survival of advanced melanoma patients treated with immunotherapy and targeted therapy: a real‐world studyYu, Su‐Yeon, Mckavanagh, Dan, McPherson, Ian, Walpole, Euan, Atkinson, Victoria and Hollingworth, Samantha (2021). Survival of advanced melanoma patients treated with immunotherapy and targeted therapy: a real‐world study. Pharmacoepidemiology and Drug Safety, 30 (10) pds.5248, 1371-1379. doi: 10.1002/pds.5248 |
|
2021 Journal Article Non‐sclerosing large duct cholangitis secondary to checkpoint inhibitionTeo, Andrew W. C., Atkinson, Victoria, Miller, Greg and Britton, Laurence (2021). Non‐sclerosing large duct cholangitis secondary to checkpoint inhibition. Internal Medicine Journal, 51 (10), 1758-1759. doi: 10.1111/imj.15524 |
|
2021 Journal Article Standard-dose pembrolizumab plus alternate-dose ipilimumab in advanced melanoma: KEYNOTE-029 cohort 1C, a phase 2 randomized study of two dosing schedulesLong, Georgina V., Robert, Caroline, Butler, Marcus O., Couture, Felix, Carlino, Matteo S., O’Day, Steven, Atkinson, Victoria, Cebon, Jonathan S., Brown, Michael P., Dalle, Stephane, Hill, Andrew G., Gibney, Geoffrey T., McCune, Steven, Menzies, Alexander M., Niu, Cuizhen, Ibrahim, Nageatte, Moreno, Blanca Homet and Diab, Adi (2021). Standard-dose pembrolizumab plus alternate-dose ipilimumab in advanced melanoma: KEYNOTE-029 cohort 1C, a phase 2 randomized study of two dosing schedules. Clinical Cancer Research, 27 (19), 5280-5288. doi: 10.1158/1078-0432.CCR-21-0793 |
|
2021 Journal Article 5-year outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation⇓positive advanced melanoma: extended follow-up of the coBRIM studyAscierto, Paolo A., Dreno, Brigitte, Larkin, James, Ribas, Antoni, Liszkay, Gabriella, Maio, Michele, Mandala, Mario, Demidov, Lev, Stroyakovskiy, Daniil, Thomas, Luc, de la Cruz-Merino, Luis, Atkinson, Victoria, Dutriaux, Caroline, Garbe, Claus, Hsu, Jessie, Jones, Surai, Li, Haocheng, McKenna, Edward, Voulgari, Athina and McArthur, Grant A. (2021). 5-year outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation⇓positive advanced melanoma: extended follow-up of the coBRIM study. Clinical Cancer Research, 27 (19), 5225-5235. doi: 10.1158/1078-0432.CCR-21-0809 |
|
2021 Journal Article Adjuvant nivolumab for stage III/IV melanoma: Evaluation of safety outcomes and association with recurrence-free survivalMandala, Mario, Larkin, James, Ascierto, Paolo Antonio, Del Vecchio, Michele, Gogas, Helen, Cowey, C. Lance, Arance, Ana, Dalle, Stéphane, Schenker, Michael, Grob, Jean-Jacques, Chiarion-Sileni, Vanna, Marquez, Ivan, Butler, Marcus O., Di Giacomo, Anna Maria, Lutzky, Jose, De La Cruz-Merino, Luis, Atkinson, Victoria, Arenberger, Petr, Hill, Andrew, Fecher, Leslie, Millward, Michael, Khushalani, Nikhil I., De Pril, Veerle, Lobo, Maurice and Weber, Jeffrey (2021). Adjuvant nivolumab for stage III/IV melanoma: Evaluation of safety outcomes and association with recurrence-free survival. Journal for ImmunoTherapy of Cancer, 9 (8) e003188, 1-9. doi: 10.1136/jitc-2021-003188 |
|
2021 Journal Article Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapyDearden, Helen, Au, Lewis, Wang, Daniel Y., Zimmer, Lisa, Eroglu, Zeynep, Smith, Jessica L., Cuvietto, Marcello, Khoo, Chloe, Atkinson, Victoria, Lo, Serigne, Long, Georgina V., Sandhu, Shahneen, Ascierto, Paolo A., Carlino, Matteo S., Johnson, Douglas B., Larkin, James and Menzies, Alexander M. (2021). Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy. European Journal of Cancer, 153, 168-178. doi: 10.1016/j.ejca.2021.04.045 |
|
2021 Journal Article Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti–PD-1 therapyHepner, Adriana, Atkinson, Victoria G., Larkin, James, Burrell, Rebecca A., Carlino, Matteo S., Johnson, Douglas B., Zimmer, Lisa, Tsai, Katy K., Klein, Oliver, Lo, Serigne N., Haydon, Andrew, Bhave, Prachi, Lyle, Megan, Pallan, Lalit, Pires da Silva, Ines, Gerard, Camille, Michielin, Olivier, Long, Georgina V. and Menzies, Alexander M. (2021). Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti–PD-1 therapy. European Journal of Cancer, 153, 213-222. doi: 10.1016/j.ejca.2021.04.021 |
|
2021 Journal Article Contemporary management of locoregionally advanced melanoma in Australia and New Zealand and the role of adjuvant systemic therapySmithers, B. Mark, Saw, Robyn P. M., Gyorki, David E., Martin, Richard C. W., Atkinson, Victoria, Haydon, Andrew, Roberts‐Thomson, Rachel and Thompson, John F. (2021). Contemporary management of locoregionally advanced melanoma in Australia and New Zealand and the role of adjuvant systemic therapy. ANZ Journal of Surgery, 91 (S2), 3-13. doi: 10.1111/ans.17051 |
|
2021 Journal Article The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysisVersluis, Judith M., Hendriks, Anne M., Weppler, Alison M., Brown, Lauren J., de Joode, Karlijn, Suijkerbuijk, Karijn P.M., Zimmer, Lisa, Kapiteijn, Ellen W., Allayous, Clara, Johnson, Douglas B., Hepner, Adriana, Mangana, Joanna, Bhave, Prachi, Jansen, Yanina J.L., Trojaniello, Claudia, Atkinson, Victoria, Storey, Lucy, Lorigan, Paul, Ascierto, Paolo A., Neyns, Bart, Haydon, Andrew, Menzies, Alexander M., Long, Georgina V., Lebbe, Celeste, van der Veldt, Astrid A.M., Carlino, Matteo S., Sandhu, Shahneen, van Tinteren, Harm, de Vries, Elisabeth G.E. ... Jalving, Mathilde (2021). The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. European Journal of Cancer, 151, 72-83. doi: 10.1016/j.ejca.2021.04.003 |
